MoonLake Immunotherapeutics (NASDAQ: MLTX)’s Post

⭐Multiple Myeloma Hub spotlight: Updated data from the phase II CARTITUDE-2 trial ⭐ At #EHA2024, Wilfried Roeloffzen from The University Medical Center Groningen discussed results from Cohort D of the phase II CARTITUDE-2 trial (NCT04133636) investigating the safety and efficacy of cilta-cel in patients with clinically high-risk NDMM who achieved <CR after ASCT frontline therapy (N = 17). The primary endpoint of MRD negativity was achieved in 80% of patients. ORR was 94.1%, 18-mo DoR rate was 93.3%, and 18-mo PFS and OS rates were 93.8% each, highlighting promising efficacy of cilta-cel ± lenalidomide maintenance in these patients. #mmsm #myeloma

In December 2023, the FDA approved a groundbreaking gene-editing treatment for sickle cell disease. Now, the final results from the pivotal clinical trial are published in the New England Journal of Medicine. This study, coauthored by UIC’s Dr. Damiano Rondelli, reveals that the therapy significantly reduces painful symptoms. We're proud of Dr. Rondelli's contributions to this major medical milestone! Read the full story: https://loom.ly/l8F4_cM #UICAlumni #MedicalBreakthrough #UIC #UICProud #SickleCellDisease #UICHealth #UICResearch

🔍 Recent research from Shuchi Gulati, MD, MSc, and colleagues found that #everolimus failed to improved #RFS in patients with #nccRCC. 🧠 Learn More:

📢 Dr Vanessa Quick and Dr Ernest Choy discuss the impact of qwTCZ cessation on #GCA patients, highlighting relapse risks and the need for better access to care. Listen to the conversation here: https://bit.ly/3Z9lJL7 or read the full article in our Rheumatology Journal: https://bit.ly/3Tf9DMV #giantcellarteritis #tocilizumab #rheumatology #BSR

Glad to share the 5th volume of our #newsletter '#NCCCR #News & #Views'. Various #articles from the #hospital covering different #updates, #activities, #initiatives, and #patient/#public-directed #information. Several #topics related to #Pharmacy including: - NCCCR’S Pioneering Role in Elevating #Hemophilia #Treatment (Amna Gameil; Rawan Dawoud, BCOP). - Shining a Light on the Role of #Clinical #Informatics #Pharmacist in NCCCR (Amir Nounou). - Navigating Life After #Bone #Marrow #Transplantation: A Guide to #Medication #Harmony (Dr. Amaal Gulied). - NCCCR Celebrates #World #Pharmacists #Day. - #Employee #Spotlight on our #Hematology #ClinicalPharmacy Specialist Dr. Amaal Gulied. Many thanks to the #editorial #team led by Dr. Salha Bujassoum Albader and including Eyad Tubishat & Maria Benkhadra for their great #efforts. #Medicine #Cancer #Oncology #Patients #Awareness

May is #LupusAwarenessMonth – and today is #WorldLupusDay! Lupus affects millions of people, so today and always, let’s show our love and support for all in the Lupus community; including our Members, who work tirelessly to bring the best care to their Lupus patients. Lupus affects each person differently, often with different symptoms. More research is needed to help find treatments, and ultimately, a cure. Specialty Networks encourages you to take time to shine light on lupus, honor every lupus champion, and celebrate all who are making a difference in the Lupus community. This past January, PPS Analytics (A Specialty Networks Company) expanded to Rheumatology. PPS is an AI-enabled technology designed to help our members identify, navigate, and engage patients to improve adherence to clinical care pathways and protocols for diagnostics and therapeutic intervention with over 21,000 active Lupus patients on the platform...and growing. Learn more: https://lnkd.in/eRYg3uty

We celebrate Clinical Trials Day on May 20, marking the start of the first randomized clinical trial by James Lind in 1747. Since then, clinical trials have evolved significantly. Today, they are essential in developing treatments for conditions like myeloma. We thank everyone involved in myeloma clinical trials, from researchers to participants, for their crucial role in advancing safe and effective treatments. #ClinicalTrialsDay #canadianmyelomaresearchgroup #MedicalAdvancements #ResearchHeroes #DrugDevelopment #HealthcareInnovation #PatientAdvocacy #ScienceProgress #ClinicalResearch

Today marks #EuropeanMyelomaDay! We're sharing a noteworthy article from the EBMT that delves into the important work of their Chronic Malignancies Working Party. 📖 Read the full article here: https://lnkd.in/d72Z9zPs #CERTAINTY #EuropeanMyelomaDay #LearnShareChange #EBMT

During #CART24, Steve Kalloger, MSc, Head of Research at LC, spoke with Healio | HemOnc Today about the experience of patients who have received CAR-T therapy. This study reveals that the mosaic of side effects experienced by those receiving CAR-T may extend beyond what is typically reported. You can read the rest of the article at: https://lnkd.in/gkkrT5Vz #lymsm

Discover the Power of Interdisciplinary Care with seca mBCA North America and inHealth Lifestyle Therapeutics! This webinar on March 29th will show you how to fill the void in traditional obesity care through our collaborative efforts. Get insights from the SECA and inHealth Lifestyle Therapeutics experts!